Mitochondrial DNA as a Potential Translational Biomarker of Mitochondrial Dysfunction in Drug‐Induced Toxicity Studies

Abstract

Mitochondrial DNA as a potential translational biomarker of mitochondrial dysfunction in drug induced toxicity studies.

Potential Mechanisms of Mitochondrial DNA Mediated Acquired Mitochondrial Disease

“…Furthermore, there is increasing evidence showing a link between patient drug response and circulating MtDNA levels showing that there is strong potential for the future use of MtDNA in the field of personalised medicine (Malik, 2017).…”

“…In addition to primary and seconday mitochondrial disease, it has been postulated that mitochondrial dysfunction plays a significant part in the pathogenesis of many common disorders including common metabolic disorders such as diabetes, cardiovascular disease, neurodegenrative diseases and cancers (Schon et al, 2012;Picard et al, 2016). A growing body of evidence implicates changes in MtDNA in cells organs and body fluids in such diseases of aquired mitochndrial dysfunction, including prevalent and chronic health conditions including neurodegenerative disease, obesity, cardiovascular disease, diabetes and its complications, fatty liver disease, and also include complications arising from drug toxicity (reviewed by Malik & Czajka, 2013, Malik, 2017. Furthermore, emerging evidence indicates that the development of mitochondrial dysfunction can also contribute to chronic inflammation and therefore may also be involved in a number of inflammatory pathways (Boyapati et al, 2017).…”